This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant neoplasm of piriform sinus조롱박오목(이상와)의 악성신생물 (이상와암)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: C12 / Special Copayment Reduction: V193 / 5% copayment (for 5 years from the date of cancer registration)
B. SynonymsPyriform sinus cancer, pyriform fossa cancer, squamous cell carcinoma of the pyriform sinus, Piriform sinus carcinoma, Pyriform fossa cancer
C. Adult onsetVery high — occurs mainly in men in their 50s–70s; rare at age 40s and younger and extremely rare in children
1. HistoryEvolution of hypopharyngeal cancer classification, establishment of a separate code for the pyriform sinus, history of the development of the larynx preservation concept
2. CausesSmoking (strongest), alcohol, synergistic effect of smoking + alcohol, deficiency anemia (Plummer-Vinson)
3. GeneticsTP53 and CDKN2A mutations, 3p14 deletion (FHIT), EGFR overexpression, somatic mutation spectrum
4. General epidemiology65–85% of hypopharyngeal cancers originate in the pyriform sinus; about 300–400 cases per year in Korea; over 90% men
5. PathophysiologyWidespread mucosal damage from tobacco and alcohol carcinogens, field cancerization, multiple primary cancers
6. SymptomsDysphagia, sore throat, otalgia (referred pain), neck mass, hoarseness, weight loss
7. SignsCervical lymphadenopathy, mucosal abnormality of the pyriform sinus on laryngoscopy, vocal cord paralysis, pooling of saliva
8. ScreeningNo national cancer screening; endoscopy for high-risk groups; immediate evaluation for persistent otalgia or odynophagia
9. DiagnosisLaryngoscopy + biopsy, CT and MRI, PET-CT, AJCC 8th edition TNM staging, transnasal esophagoscopy
10. TreatmentLaryngopharyngectomy, larynx-preserving CCRT, induction chemotherapy followed by CCRT, combination with immunotherapy
11. Prognosis5-year survival stage I 100%, stage II 60–70%, stage III 45–55%, stage IV 25–35%; overall 35–45%
12. PreventionSmoking cessation (top priority), limiting alcohol, treatment of Plummer-Vinson anemia, early evaluation of otalgia and odynophagia
13. ReferencesLefebvre JL et al. J Natl Cancer Inst 1996 and 9 other papers

1. History

The pyriform sinus is a component of the hypopharynx, a pear-shaped recess located lateral to the larynx. Historical descriptions of malignant tumors arising at this site began with the development of head and neck surgery in the late 19th century. Initially, laryngeal and hypopharyngeal cancers were described together, and they began to be classified as independent subtypes according to anatomic and clinical features only from the early 20th century.

In 1952, Lederman systematically classified hypopharyngeal cancer into three regions — the pyriform sinus, the posterior pharyngeal wall and the posterior surface of the epiglottis — establishing pyriform sinus carcinoma as a distinct clinical entity. Epidemiologic studies subsequently confirmed that the pyriform sinus is the most common site, accounting for 65–85% of hypopharyngeal cancers. In the 1970s, surgery (total laryngopharyngectomy) was the only curative treatment, but permanent tracheostomy and reduced quality of life were serious problems. A 1996 study by the French GETTEC group (Lefebvre et al.) was the first randomized controlled trial to demonstrate the possibility of larynx preservation with induction chemotherapy followed by radiotherapy, a historic turning point that shifted the treatment paradigm from surgery-centered to organ preservation–centered.

In Korea, specialized head and neck oncology groups formed from the 1990s, and Korean data on hypopharyngeal cancer were systematically accumulated. With the introduction of IMRT and concurrent chemoradiotherapy, laryngeal function preservation rates and survival rates have both improved since the 2000s. Recently, new treatment concepts such as robot-assisted transoral surgery and combination therapy with immune checkpoint inhibitors are in clinical research. ICD-10 code C12 specifies only the pyriform sinus and is distinguished from other sites of the hypopharynx (C13).


2. Causes

Environmental factors centered on smoking and alcohol overwhelmingly dominate the causes of pyriform sinus cancer. Smoking is the strongest risk factor for pyriform sinus cancer, showing a dose-response relationship between amount smoked (pack-years) and risk. Polycyclic aromatic hydrocarbons (PAHs), nitrosamines, acrolein and other substances in tobacco smoke directly cause DNA damage in the hypopharyngeal mucosal epithelium. Pyriform sinus cancer is very rare in nonsmokers, and it is estimated that most pyriform sinus cancers would not have occurred without smoking.

Alcohol consumption increases risk independently of smoking, but combined exposure to the two factors produces a much stronger increase in risk than either exposure alone. Acetaldehyde, a metabolite of alcohol, acts as a direct carcinogen, and alcohol-induced increases in mucosal permeability promote the penetration of other carcinogens into the epithelium. People who both smoke and drink are reported to have a 10–30-fold or greater increase in risk compared with nonsmoking nondrinkers.

Plummer-Vinson (Patterson-Kelly) syndrome is a rare condition characterized by deficiency anemia (iron deficiency), dysphagia and atrophy of the oral and pharyngeal mucosa, and it increases the risk of nasopharyngeal and pyriform sinus carcinoma. This is thought to involve mucosal fragility due to iron deficiency. HPV (human papillomavirus) plays an important role in oropharyngeal cancer, but its role in pyriform sinus cancer is limited compared with the oropharynx. Some associations have also been reported with occupational carcinogens (asbestos, sulfuric acid mist, wood dust).


3. Genetics

The main molecular biological features of pyriform sinus cancer are shared with smoking-related head and neck squamous cell carcinoma (HNSCC). TP53 mutations are the most common somatic mutations in hypopharyngeal squamous cell carcinoma, found in 40–60% of cases, mainly with a smoking-related transversion (C→A, G→T) pattern. Loss of TP53 function disables the DNA damage checkpoint and promotes genomic instability.

CDKN2A (p16/INK4A) deletion disrupts the p16/CDK4/RB cell-cycle regulatory axis, bypassing the G1 cell-cycle checkpoint. Deletion of the FHIT gene in the 3p14 region is frequent in smoking-related head and neck cancers and is involved in purine metabolism and apoptosis regulation. Chromosomal deletions at 9p21, 11q22, 13q14 and other loci have also been reported. EGFR (HER1) is overexpressed in about 70–90% of hypopharyngeal squamous cell carcinomas, providing the basis for targeted therapy. PIK3CA mutations are observed in about 10–15%.

Pharmacogenomically, variants in genes related to platinum (cisplatin, carboplatin) sensitivity and resistance (ERCC1, ERCC2, XPC) are being studied for predicting treatment response. ALDH2 variants related to alcohol metabolism (common in East Asians) cause acetaldehyde accumulation and increase the risk of upper aerodigestive tract cancers. PD-L1 expression has been reported as positive in 40–60% of head and neck squamous cell carcinomas including pyriform sinus cancer, providing the basis for immune checkpoint inhibitor therapy. Helicase (POLE) mutations or high tumor mutational burden (TMB-H) are rarely observed and may be used to predict subtypes with excellent response to immunotherapy.


4. General epidemiology

Pyriform sinus cancer (C12) is the most common subtype of hypopharyngeal cancer; about 65–85% of cancers arising in the hypopharynx have the pyriform sinus as the primary site. In terms of the incidence of the hypopharynx as a whole, it is a rare cancer in Western countries at about 0.5–2 per 100,000 population, but it is relatively more common in countries with high smoking rates (France, parts of Eastern Europe). In Korea, the annual incidence of hypopharyngeal cancer (C12+C13) is about 400–600 cases, accounting for about 0.15–0.2% of all cancers.

Sex distribution: men overwhelmingly predominate, with a male-to-female ratio reaching 8–10:1, reflecting sex differences in smoking and drinking. Age is concentrated in the 50s–70s, and it is rare at age 40s and younger. Geographically, incidence has traditionally been high in Central and Eastern Europe, especially France and Eastern Europe, but it is declining in Western countries due to tobacco control policies. In Korea and Japan, despite declining smoking rates, a sharp decrease in the absolute number of cases is not yet evident because of the growing elderly population.

The stage distribution at diagnosis is very unfavorable, with about 60–70% diagnosed at stage III–IV. This is because the pyriform sinus is anatomically hidden and early symptoms are mild, so patients seek care late. The risk of a second primary tumor is high, and synchronous or metachronous occurrence with esophageal, lung and oropharyngeal cancers is explained by the common risk factors of smoking and alcohol (field cancerization). Follow-up examinations that take this into account are important in post-treatment management.


5. Pathophysiology

The pathogenesis of pyriform sinus cancer is best explained by the concept of field cancerization. When the entire mucosa of the upper aerodigestive tract is chronically exposed to carcinogens from tobacco and alcohol, independent genetic alterations accumulate at multiple sites of the mucosal epithelium. This is called a mucosal field defect and is the background for synchronous or metachronous multiple cancers arising at several sites such as the pyriform sinus, oropharynx, oral cavity, esophagus and lungs.

The molecular multistep carcinogenic process begins with cell immortalization due to early mutations such as TP53 and CDKN2A, followed by telomerase activation, activation of growth signaling pathways such as EGFR and KRAS, induction of angiogenesis (VEGF overexpression), and finally destruction of the basement membrane and acquisition of invasive and metastatic capacity. Because of the anatomic features of the pyriform sinus, the tumor can spread extensively along the submucosal space, so the actual extent of invasion is often wider than the visible tumor.

In particular, when the squamous epithelium lining the pyriform sinus is repeatedly damaged chemically, it progresses through dysplasia to carcinoma in situ and invasive carcinoma. The rich submucosal lymphatic network around the pyriform sinus facilitates early lymph node metastasis. Cervical level II–IV lymph nodes and retropharyngeal lymph nodes are the first sites of metastasis, and even when the primary tumor is small, lymph node metastasis is often already present at diagnosis (occult metastasis rate 38–50% even when clinically N0).


6. Symptoms

Early symptoms of pyriform sinus cancer are nonspecific and are often mistaken for pharyngitis or gastroesophageal reflux. The most common early symptoms are pain on swallowing (odynophagia) or a foreign-body sensation in the throat, which progresses to dysphagia for solids. Otalgia, i.e., referred pain to the ear, is a characteristic symptom of pyriform sinus cancer, caused by referred pain via the vagus nerve (Arnold's nerve) or glossopharyngeal nerve (Jacobson's nerve). In adults with otalgia but a normal ear examination, the hypopharynx and oropharynx must be evaluated.

About 40–60% of patients report a neck mass at the first visit, and in some cases an asymptomatic neck mass is the only symptom. Hoarseness suggests vocal cord paralysis due to laryngeal invasion by the tumor or involvement of the recurrent laryngeal nerve. Cough due to aspiration of food or liquids and aspiration pneumonia are also symptoms of advanced disease. Weight loss results from a combination of dysphagia and the metabolic effects of cancer. Rarely, hemoptysis or blood-stained saliva may occur. Stridor due to laryngeal obstruction indicates an emergency in very advanced lesions.

An average of 3–6 months is reported to elapse from symptom onset to diagnosis of pyriform sinus cancer, due to the nonspecific nature of early symptoms and late presentation by patients. Smokers or drinkers with any of sore throat, otalgia, dysphagia or a neck mass lasting 3 weeks or more should be evaluated promptly by a head and neck specialist.


7. Signs

The most common sign on physical examination is cervical lymphadenopathy. Jugulodigastric or jugulo-omohyoid lymph nodes are palpated as hard and nontender. Bilateral neck masses are not uncommon. When the pyriform sinus is observed by laryngoscopy or flexible laryngoscopy, asymmetry of the normal mucosa, erythema, ulceration, an elevated mass and pooling of saliva within the pyriform sinus are observed. Pooling of saliva is an important sign suggesting reduced mucosal sensation or anatomic obstruction within the pyriform sinus.

Vocal cord paralysis indicates involvement of the recurrent laryngeal nerve, with unilateral or bilateral fixation of the vocal cords. Vocal cord paralysis implies accompanying laryngeal invasion and therefore affects the stage. When the tumor invades the posterior wall of the hypopharynx, fixation of the neck tissues may be palpated. Large metastatic cervical lymph nodes may adhere to the internal jugular vein or sternocleidomastoid muscle, limiting mobility. Blood tests often show accompanying chronic conditions related to smoking and drinking (anemia, abnormal liver function). Tumor markers such as CEA (carcinoembryonic antigen) have low specificity in squamous cell carcinoma and are used as an adjunct for follow-up rather than diagnosis.

Systemic signs include malnutrition (weight loss due to dysphagia, hypoalbuminemia) and dehydration, and in advanced lesions dyspnea and stridor may occur, sometimes requiring emergency airway management. Therefore, evaluation of airway status and respiratory function is essential at the first visit.


8. Screening

Currently, no national cancer screening program for pyriform sinus cancer (C12) or hypopharyngeal cancer exists in Korea. This is because the incidence is relatively low and cost-effectiveness analyses of large-scale population screening are insufficient. However, clinically guided evaluation is needed for high-risk groups (age 55 and over, smoking history of 30 pack-years or more, heavy drinkers).

Red flag symptoms include unilateral sore throat, dysphagia, otalgia and a neck mass lasting 3 weeks or more; in these cases, primary care providers should refer immediately to a head and neck specialist or otolaryngologist. Flexible laryngoscopy can be performed quickly in the outpatient clinic and allows direct identification of mucosal abnormalities of the pyriform sinus. Because this test is minimally invasive and inexpensive, it is the frontline tool for evaluating high-risk groups.

As a program for early detection of pyriform sinus cancer, the UK NHS has established a rapid diagnostic pathway for patients with warning symptoms through the Two-Week Wait rule (referral to a specialist within 2 weeks). In Korea, too, the early detection system needs to be strengthened through regular oral and pharyngeal mucosal examination and endoscopic evaluation of smokers and drinkers. Because synchronous esophageal cancer is likely, simultaneous evaluation of the esophagus by upper gastrointestinal endoscopy is recommended at diagnosis.


9. Diagnosis

Pyriform sinus cancer is confirmed by biopsy under laryngoscopy. The pyriform sinus lesion is directly visualized with a flexible or rigid laryngoscope and forceps biopsy is performed. For small lesions or when submucosal infiltration is suspected, planned biopsy by direct laryngoscopy under general anesthesia is needed. Esophagoscopy or bronchoscopy is performed at the same time to exclude a synchronous second primary cancer (panendoscopy).

Among imaging tests, CT (contrast-enhanced neck and chest) is essential for evaluating tumor extent, cervical lymph node metastasis and thoracic metastasis (lungs, mediastinum). MRI is superior to CT for evaluating soft tissue invasion, especially invasion of the pyriform sinus apex and the outer laryngeal framework, and proximity to the carotid artery. PET-CT is used to detect distant metastasis and occult synchronous primary cancers. EUS (endoscopic ultrasound) may be used as an adjunct for evaluating cervical lymph nodes.

AJCC 8th edition TNM staging: T1 is confined to one subsite of the pyriform sinus and 6 cm or less; T2 involves more than one subsite of the pyriform sinus or the larynx; T3 involves vocal cord fixation or invasion of the pyriform sinus apex, or invasion of the esophageal or postcricoid mucosa; T4a involves invasion of the thyroid, cricoid or arytenoid cartilage, hyoid bone, esophagus or neck soft tissue; T4b involves invasion of the prevertebral fascia, carotid artery or mediastinum. N and M staging are the same as for other head and neck cancers. Histopathology is mostly squamous cell carcinoma, and PD-L1 CPS score, EGFR expression and tumor mutational burden (TMB) are used in treatment decisions.


10. Treatment

The treatment strategy for pyriform sinus cancer is determined by stage, laryngeal involvement and the patient's general condition. For early lesions (T1N0, T2N0), surgery or radiotherapy alone are options, but because pyriform sinus cancer is rarely detected early, treatment usually begins at an advanced stage. The traditional standard treatment for advanced pyriform sinus cancer was total laryngopharyngectomy + bilateral neck dissection + postoperative radiotherapy (or CCRT), but this results in permanent tracheostomy and loss of voice.

Currently, larynx-preserving treatment has become a major option. In patients who respond well to induction chemotherapy (TPF: docetaxel + cisplatin + 5-FU, or PF: cisplatin + 5-FU), concurrent chemoradiotherapy (CCRT) is given to preserve the larynx. This approach was validated in the 1996 GETTEC study, and the 5-year laryngeal function preservation rate is reported to be about 35–45%. Radiation in CCRT uses IMRT, and cisplatin (100 mg/m² every 3 weeks) is the most commonly used concurrent agent.

For recurrent or metastatic pyriform sinus cancer, the EXTREME regimen (cetuximab + platinum + 5-FU) had been established as standard first-line treatment, but recently in the KEYNOTE-048 study, pembrolizumab alone or pembrolizumab + chemotherapy showed a survival benefit in head and neck squamous cell carcinoma with CPS≥1 and became the new standard. Nivolumab is also approved as second-line treatment for platinum-refractory head and neck squamous cell carcinoma. The EGFR-targeted agent cetuximab can be used in combination with radiation or alone.


11. Prognosis

Pyriform sinus cancer is one of the head and neck cancers with the worst prognosis. The overall 5-year survival rate is about 30–45%, lower than that of other head and neck cancers (oral cavity cancer, oropharyngeal cancer, supraglottic laryngeal cancer). This is because the disease is often already advanced at diagnosis, complete resection is difficult because of adjacent critical anatomic structures, and the risk of distant metastasis is high. 5-year survival by stage is reported as about 95–100% for stage I, about 60–70% for stage II, about 40–55% for stage III, about 25–35% for stage IVA and about 10–20% for stage IVB–C (distant metastasis).

Important prognostic factors are T stage, N stage, surgical margin status and the presence of vocal cord paralysis. Response to induction chemotherapy (complete vs. partial response) is an important predictor of successful larynx preservation and long-term survival. PD-L1 CPS score is used to predict response to immune checkpoint inhibitor therapy. The occurrence of a second (metachronous) primary cancer has an important impact on prognosis in long-term follow-up, and a systematic follow-up examination program is needed for this. Patients who retain a functional larynx after larynx-preserving treatment have markedly higher quality of life than patients with a permanent tracheostomy.

In the recurrence pattern, both local recurrence (pharynx, larynx, cervical lymph nodes) and distant metastasis (lungs, liver, bone, mediastinum) are common. Postoperative adjuvant CCRT lowers the recurrence rate in high-risk patients with positive margins or extracapsular nodal extension. Salvage surgery is considered for patients with local recurrence after radiotherapy, but morbidity is high and the rate of complete resection is low. In the palliative setting, a multidisciplinary approach focused on maintaining quality of life and relieving symptoms (dysphagia, pain, airway management) is important.


12. Prevention

The most effective prevention of pyriform sinus cancer is smoking cessation. When smoking stops, hypopharyngeal mucosal damage decreases and risk falls over time, but smoking-related risk remains significant for 10–15 years after quitting. Early cessation is therefore very important, and pharmacologic cessation aids such as nicotine replacement therapy and varenicline should be actively recommended. Reducing alcohol intake also lowers risk independently, and switching from distilled spirits (soju, whisky) to relatively less hazardous low-alcohol drinks may play a supporting role.

In Plummer-Vinson syndrome, treatment of iron deficiency (iron supplements, dietary correction) contributes to normalization of the mucosa, and a resulting reduction in the risk of pyriform sinus cancer has been reported. Improving nutritional status is also important from a preventive standpoint. A diet rich in vegetables, fruit and vitamins C, E and A is known to lower cancer risk. HPV vaccines are effective in preventing oropharyngeal cancer, but a direct preventive effect against pyriform sinus cancer has not yet been sufficiently demonstrated.

Building an early detection system through regular inspection of the oral and pharyngeal mucosa in high-risk groups (smokers, drinkers, age 50 and over) and immediate endoscopic evaluation of abnormal symptoms is clinically the most realistic prevention and early detection strategy. The system by which primary care providers recognize warning signs early and promptly refer patients to head and neck specialists needs to be strengthened. Thorough industrial hygiene management of exposure to carcinogens such as asbestos, aromatic amines and sulfuric acid mist in the workplace is also a secondary preventive measure.


13. References

  1. Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European organization for research and treatment of cancer phase III trial. J Natl Cancer Inst. 1996;88(13):890-899.
  2. Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011;100(1):33-40.
  3. Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048). Lancet. 2019;394(10212):1915-1928.
  4. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349(22):2091-2098.
  5. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856-1867.
  6. Takes RP, Strojan P, Silver CE, et al. Current trends in initial management of hypopharyngeal cancer: the declining use of open surgery. Head Neck. 2012;34(2):270-281.
  7. Pignon JP, le Maître A, Maillard E, Bourhis J; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4-14.
  8. Slootweg PJ, Ferlito A, Devaney KO, et al. The phenotype of epithelial malignancies of the hypopharynx. Eur Arch Otorhinolaryngol. 2005;262(11):861-864.
  9. Kim SY, Park B, Hwang E, et al. Surgical outcomes of head and neck cancers in patients over 75 years of age in Korea. Clin Exp Otorhinolaryngol. 2019;12(4):412-419.
  10. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116-1127.